Johnson&Johnson COVID-19 vaccine trial data shows it is effective after a single dose

Embargoed until: Publicly released: 2021-04-22 07:00

International

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

Data from the phase 3 trial of the Johnson&Johnson COVID-19 vaccine has revealed a single dose of the vaccine has a 66 per cent efficacy against moderate to severe or critical COVID-19 one month after vaccination. The efficacy of the vaccine was even higher against severe or critical Covid-19, sitting at 85 per cent. Data from the South African arm of the trial shows that although the majority of cases had the 20H/501Y.V2 variant, the vaccine remained similarly effective.